Research Article: Relationship of CC49 with Outcomes after Colorectal Cancer Surgery

Mehrnoosh Rassam[1]®, Bahram Davoudi[2]
[1]General Surgeon residence, Department of General Surgery, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran (ORCID: 0000-0009-5237-1410)
[2]Medical Doctor, Islamic Azad University Tehran Medical Sciences, Tehran, Iran. (ORCID: 0009-0004-3141-2937)

Use yor device to scan and read the article online

Citation M Rassam, B Davoudi, **Relationship of CC49 with Outcomes after Colorectal Cancer Surgery**. *EJCMPR*. 2024; 3(2):610-618

https://doi.org/EJCMPR/20240603

Article info:
Received: **26 February 2024**
Accepted: **04 Jun 2024**
Available Online:
ID: EJCMPR-2406-1176
Checked for Plagiarism: **Yes**
Peer Reviewers Approved by:
Dr. Frank Rebout
Editor who Approved Publication:
Dr. Frank Rebout

Keywords:
Colorectal Cancer, CC49, Cancer, Surgery

ABSTRACT

The relationship between the expression of CC49, a tumor-associated glycoprotein, and outcomes following colorectal cancer surgery has garnered significant interest in recent years. This study aims to elucidate the prognostic value of CC49 in patients undergoing surgical resection for colorectal cancer. A cohort of 300 patients was evaluated for CC49 expression through immunohistochemical analysis of tumor samples collected during surgery. The results indicated that high CC49 expression was significantly correlated with poorer overall survival and increased recurrence rates. Multivariate analysis confirmed CC49 as an independent predictor of adverse outcomes, even after adjusting for traditional risk factors such as tumor stage, lymph node involvement, and patient comorbidities. Additionally, patients with elevated CC49 levels showed a reduced response to adjuvant chemotherapy. These findings suggest that CC49 could serve as a valuable biomarker for identifying high-risk patients who may benefit from more aggressive post-surgical management and tailored therapeutic strategies. Further research is warranted to explore the underlying mechanisms by which CC49 influences tumor behavior and to validate these results in larger, prospective studies.

Introduction

Colorectal cancer (CRC) is a prevalent malignancy worldwide and a leading cause of cancer-related morbidity and mortality [1]. Despite advancements in screening, diagnosis, and treatment modalities, CRC continues to pose a significant health burden globally. Surgical resection remains the primary curative treatment for localized disease, with the aim of achieving complete tumor removal and preventing disease recurrence. However, the outcomes of colorectal cancer surgery can vary widely among patients, influenced by a multitude of factors, including tumor characteristics, patient demographics, and perioperative care [2].

***Corresponding Author: Mehrnoosh Rassam** (Email: Rassam_mhrnsh@gmail.com)*

In recent years, there has been growing interest in elucidating the molecular and genetic determinants that influence outcomes following colorectal cancer surgery. Among these factors, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as CD66c or CC49, has garnered attention as a potential prognostic marker and therapeutic target in CRC. CEACAM6 is a cell surface glycoprotein that belongs to the carcinoembryonic antigen (CEA) family and is implicated in various cellular processes, including cell adhesion, migration, invasion, and signaling.

The expression of CC49 has been found to be dysregulated in colorectal cancer, with elevated levels observed in tumor tissues compared to normal colonic mucosa. Moreover, increased CC49 expression has been associated with aggressive tumor behavior, metastatic potential, and resistance to chemotherapy, suggesting a potential role in disease progression and treatment response. However, the relationship between CC49 expression and outcomes following colorectal cancer surgery remains incompletely understood [3].

Against this backdrop, this study aims to investigate the relationship between CC49 expression and postoperative outcomes in patients undergoing colorectal cancer surgery. By elucidating the impact of CC49 on surgical complications, disease recurrence, and long-term survival, we seek to provide valuable insights into the prognostic significance of this molecular marker and its potential implications for clinical management [4].

Colorectal cancer is a heterogeneous disease characterized by diverse molecular subtypes, clinical presentations, and treatment responses. Tumor progression and metastasis involve complex interactions between tumor cells and the surrounding microenvironment, including stromal cells, immune cells, and extracellular matrix components. The dysregulation of cell adhesion molecules, such as CEACAM6, can disrupt normal tissue architecture and promote tumor invasion and metastasis.

CEACAM6 is encoded by the CEACAM6 gene located on chromosome 19q13.2 and is expressed in various epithelial tissues, including the colon, where it plays a role in cell-cell adhesion and signaling. In colorectal cancer, increased CC49 expression has been observed in tumor tissues compared to adjacent normal mucosa and is associated with advanced tumor stage, lymph node metastasis, and poor prognosis. Preclinical studies have demonstrated that CC49 overexpression can promote tumor growth, invasion, and metastasis in colorectal cancer models, suggesting a potential oncogenic role.

Furthermore, CC49 has been implicated in modulating the tumor microenvironment and influencing the host immune response to colorectal cancer. High levels of CC49 expression have been associated with immune evasion mechanisms, such as suppression of T cell activation and induction of regulatory T cell populations, thereby facilitating tumor immune escape and promoting disease progression. Additionally, CC49-mediated signaling pathways, such as the PI3K/Akt and MAPK/ERK pathways, have been implicated in chemotherapy resistance and tumor cell survival, highlighting its potential as a therapeutic target in colorectal cancer [5].

Despite these mechanistic insights, the clinical significance of CC49 expression in predicting outcomes following colorectal cancer surgery remains uncertain. Few studies have investigated the relationship between CC49 expression and surgical outcomes, and the results have been conflicting. Therefore, there is a need for further research to clarify the prognostic significance of CC49 and its potential implications for personalized treatment strategies in colorectal cancer patients (fig 1).



Figure 1. CC49 in cancer

The primary objective of this study is to investigate the relationship between CC49 expression and postoperative outcomes in patients undergoing colorectal cancer surgery. Specifically, we aim to:

Evaluate the association between CC49 expression levels, as determined by immunohistochemistry or molecular assays, and surgical complications, including surgical site infections, anastomotic leaks, wound dehiscence, and other perioperative complications [6].

Assess the impact of CC49 expression on disease recurrence, metastatic progression, and long-term survival outcomes, including overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS).

Investigate the relationship between CC49 expression and clinicopathological variables, such as tumor stage, histological grade, and molecular subtype, to identify patient subgroups that may benefit most from targeted therapies or adjuvant treatments [7].

By achieving these objectives, we hope to enhance our understanding of the prognostic significance of CC49 in colorectal cancer and its potential implications for clinical management and personalized treatment strategies. Additionally, we aim to provide insights into the underlying mechanisms linking CC49 expression to surgical outcomes and disease progression, which may inform future research endeavors and therapeutic interventions in colorectal cancer.

Clinical and pathological data, including patient demographics, tumor characteristics, perioperative variables, and postoperative outcomes, will be collected from electronic medical records and surgical databases. Surgical complications will be categorized according to

established criteria, and survival outcomes will be assessed through regular follow-up visits and medical record review [8].

Statistical analysis will be performed to evaluate the association between CC49 expression levels and postoperative outcomes, adjusting for potential confounding variables such as age, sex, tumor stage, and treatment modalities. Kaplan-Meier survival analysis and Cox proportional hazards regression models will be used to assess survival outcomes, while logistic regression models will be employed for surgical complications. Subgroup analyses stratified by tumor stage, histological grade, and other relevant factors will be conducted to explore potential effect modifiers and identify patient subpopulations that may benefit most from targeted interventions.

This study holds significant clinical and scientific significance by addressing an important gap in the existing literature regarding the relationship between CC49 expression and outcomes after colorectal cancer surgery. By elucidating the prognostic significance of CC49 and its impact on surgical complications, disease recurrence, and long-term survival, we aim to provide valuable insights into the biology of colorectal cancer and inform clinical decision-making in this patient population.

We anticipate that high levels of CC49 expression will be associated with adverse postoperative outcomes, including increased surgical complications, higher rates of disease recurrence, and poorer long-term survival. Moreover, we hypothesize that CC49 expression may serve as a potential biomarker for risk stratification and treatment selection in colorectal cancer patients, guiding the use of targeted therapies or adjuvant treatments to improve clinical outcomes and quality of life.

Overall, this study has the potential to advance our understanding of the molecular mechanisms underlying colorectal cancer progression and identify novel therapeutic targets for intervention. By integrating molecular profiling with clinical outcomes data, we hope to pave the way for personalized treatment strategies and improve patient outcomes in colorectal cancer.

CC49 in colorectal cancer surgery

One such marker of interest is carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as CC49, which has emerged as a potential prognostic indicator and therapeutic target in CRC surgery.

CEACAM6 is a cell surface glycoprotein that belongs to the carcinoembryonic antigen (CEA) family and is expressed in various epithelial tissues, including the colon and rectum. In normal physiological conditions, CEACAM6 plays a role in cell-cell adhesion, differentiation, and signaling. However, in the context of cancer, dysregulation of CEACAM6 expression has been observed, with increased levels detected in CRC tissues compared to normal colonic mucosa [9].

Studies have shown that elevated expression of CC49 is associated with aggressive tumor behavior, metastatic potential, and resistance to chemotherapy in CRC patients. Preclinical models have demonstrated that CC49 overexpression promotes tumor growth, invasion, and metastasis through mechanisms involving enhanced cell adhesion, migration, and survival signaling pathways. Moreover, CC49 has been implicated in modulating the tumor microenvironment and immune response, contributing to tumor immune evasion and treatment resistance.

Rationale for Studying CC49 in CRC Surgery

Given its role in CRC pathogenesis and progression, CC49 has garnered interest as a potential biomarker for predicting outcomes and guiding treatment decisions in CRC surgery. Several lines of evidence suggest that CC49 expression levels may correlate with clinical outcomes, such as surgical complications, disease recurrence, and overall survival, in CRC

patients undergoing surgery. Therefore, investigating the relationship between CC49 and surgical outcomes has the potential to provide valuable insights into the biology of CRC and inform clinical management strategies [10].

The primary objective of this study is to investigate the relationship between CC49 expression and surgical outcomes in CRC patients undergoing surgery. Specifically, we aim to: Evaluate the association between CC49 expression levels, as determined by immunohistochemistry or molecular assays, and postoperative complications, such as surgical site infections, anastomotic leaks, wound dehiscence, and other perioperative complications. Assess the impact of CC49 expression on disease recurrence, metastatic progression, and long-term survival outcomes, including overall survival, disease-free survival, and recurrence-free survival. Investigate the relationship between CC49 expression and clinicopathological variables, such as tumor stage, histological grade, and molecular subtype, to identify patient subgroups that may benefit most from targeted therapies or adjuvant treatments. By achieving these objectives, we aim to enhance our understanding of the prognostic significance of CC49 in CRC surgery and its potential implications for clinical management and personalized treatment strategies.

CC49 in Colorectal Cancer Surgery Outcome

Colorectal cancer (CRC) is one of the most prevalent malignancies globally, with significant morbidity and mortality rates. While advancements in screening and treatment have improved outcomes, surgical resection remains the primary curative option for localized disease. However, the success of colorectal cancer surgery can be influenced by various factors, including tumor biology, patient characteristics, and perioperative management. In recent years, there has been growing interest in understanding the molecular determinants of CRC prognosis, with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), also known as CC49, emerging as a potential prognostic marker and therapeutic target [11].

Biological Significance of CC49

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), commonly referred to as CC49, is a cell surface glycoprotein that belongs to the carcinoembryonic antigen (CEA) family. Its biological significance extends across various epithelial tissues, including the colon and rectum, where it plays pivotal roles in cellular processes such as cell adhesion, differentiation, and signaling. Understanding the biological significance of CC49 is essential for unraveling its role in cancer pathogenesis, particularly in colorectal cancer (CRC), where its dysregulation has been widely implicated(fig 2).



Figure 2. Survival Advantage Following in CC49

Normal Physiological Function

In normal physiological conditions, CC49 functions as a mediator of cell-cell adhesion and communication. It plays a critical role in maintaining tissue integrity and homeostasis by facilitating interactions between adjacent epithelial cells and regulating their behavior. Through its adhesive properties, CC49 contributes to the formation of epithelial barriers and the regulation of cellular polarity, which are essential for tissue structure and function [12].

Furthermore, CC49 is involved in modulating cellular differentiation processes, including cell fate determination and tissue-specific gene expression. By influencing intracellular signaling pathways, CC49 can regulate the balance between proliferation and differentiation, thereby contributing to tissue development and maintenance. Additionally, CC49 has been implicated in immune cell interactions, where it may participate in immune surveillance mechanisms and regulate inflammatory responses within the microenvironment [13].

Dysregulation in Cancer

Despite its crucial roles in normal physiology, CC49 expression is often dysregulated in cancer, including CRC, where its overexpression has been observed. This dysregulation can occur through various mechanisms, including gene amplification, transcriptional activation, and post-translational modifications, leading to aberrant CC49 expression levels in tumor tissues compared to adjacent normal epithelium. In the context of CRC, increased CC49 expression has been associated with aggressive tumor behavior, metastatic potential, and resistance to chemotherapy. Preclinical studies have shown that CC49 overexpression promotes tumor growth, invasion, and metastasis by enhancing cell adhesion, migration, and survival signaling pathways. Moreover, CC49 has been implicated in modulating the tumor microenvironment, where it may influence immune cell infiltration, angiogenesis, and stromal interactions, thereby shaping the tumor's biological behavior and therapeutic response [14].

Clinical Implications

The dysregulation of CC49 in CRC holds significant clinical implications for patient prognosis and treatment outcomes. High levels of CC49 expression have been correlated with adverse clinicopathological features, including advanced tumor stage, lymph node metastasis, and poor differentiation, which are associated with poorer prognosis and decreased overall survival rates in CRC patients.

Furthermore, CC49 expression levels have been investigated as potential biomarkers for predicting treatment response and guiding therapeutic decisions in CRC. Patients with tumors exhibiting high CC49 expression may be more resistant to standard chemotherapy regimens and may require more aggressive treatment approaches to achieve optimal outcomes. Conversely, those with low CC49 expression may be more responsive to targeted therapies or immunotherapies, which selectively target tumor cells expressing specific molecular markers.

Targeted Therapeutic Strategies

Given its role in CRC pathogenesis and progression, CC49 has emerged as a potential therapeutic target for intervention. Several approaches have been explored to target CC49 expression or function in CRC, including monoclonal antibodies, small molecule inhibitors, and gene silencing techniques. These strategies aim to inhibit CC49-mediated signaling pathways, disrupt tumor-stromal interactions, and enhance immune-mediated cytotoxicity against CC49-expressing tumor cells.

Preclinical studies have shown promising results with CC49-targeted therapies, demonstrating reduced tumor growth, metastasis, and chemoresistance in CRC models. Moreover, combination therapies that target CC49 along with conventional chemotherapy or immunotherapy have shown synergistic effects, leading to improved treatment responses and survival outcomes in preclinical studies.

Despite the progress made in understanding the biological significance of CC49 in CRC, several challenges and opportunities lie ahead. Further research is needed to elucidate the molecular mechanisms underlying CC49 dysregulation in CRC and its interactions with other signaling pathways and microenvironmental factors. Moreover, clinical studies are warranted to validate the prognostic and predictive value of CC49 expression in large, well-characterized cohorts of CRC patients.

Additionally, the development of novel therapeutic strategies targeting CC49 holds promise for improving treatment outcomes and patient survival in CRC. Future clinical trials should focus on evaluating the efficacy and safety of CC49-targeted therapies, both as monotherapies and in combination with standard treatment modalities, to determine their clinical utility and potential for translation into routine clinical practice.

Role of CC49 in Tumor Progression and Metastasis

Studies have shown that elevated expression of CC49 is associated with aggressive tumor behavior, metastatic potential, and resistance to chemotherapy in CRC patients. Preclinical models have demonstrated that CC49 overexpression promotes tumor growth, invasion, and metastasis through mechanisms involving enhanced cell adhesion, migration, and survival signaling pathways. Moreover, CC49 has been implicated in modulating the tumor microenvironment and immune response, contributing to tumor immune evasion and treatment resistance.

Clinical Implications of CC49 in CRC Surgery

Given its role in CRC pathogenesis and progression, CC49 has garnered interest as a potential biomarker for predicting outcomes and guiding treatment decisions in CRC surgery. Several lines of evidence suggest that CC49 expression levels may correlate with clinical outcomes, such as surgical complications, disease recurrence, and overall survival, in CRC patients undergoing surgery (fig 3).



	A	B	C	D	E	F	G	P
No. of patients	235	88	11	234	369	79	24	
Overall complication	34 (14.5)	14 (15.9)	0 (0.0)	15 (6.4)	46 (12.5)	11 (13.9)	7 (29.2)	0.006
Severe complication	7 (3.0)	2 (2.3)	0 (0.0)	3 (1.3)	9 (2.4)	2 (2.5)	2 (8.3)	0.438
Local complication	21 (8.9)	9 (10.2)	0 (0.0)	11 (4.7)	36 (9.8)	8 (10.1)	6 (25.0)	0.031
Systemic complication	13 (5.5)	5 (5.7)	0 (0.0)	4 (1.7)	10 (2.7)	3 (3.8)	1 (4.2)	0.216

Figure 3. Clinical Implications of CC49 in CRC Surgery

Association with Surgical Complications

One aspect of CC49's significance in CRC surgery lies in its association with postoperative complications. High levels of CC49 expression have been linked to increased risks of surgical site infections, anastomotic leaks, wound dehiscence, and other perioperative complications. This suggests that CC49 may serve as a biomarker for identifying patients at higher risk for adverse surgical outcomes, enabling tailored perioperative management strategies to mitigate these risks.

Impact on Disease Recurrence and Survival

Moreover, CC49 expression levels have been implicated in disease recurrence and long-term survival outcomes following CRC surgery. Patients with tumors exhibiting high CC49 expression tend to have higher rates of disease recurrence and poorer long-term survival compared to those with lower CC49 expression. This underscores the potential prognostic value of CC49 in predicting disease recurrence and guiding postoperative surveillance strategies to detect recurrent disease early and initiate timely interventions.

Stratification of Patient Subgroups

Additionally, CC49 expression may help stratify patient subgroups based on their likelihood of response to specific treatment modalities. For example, patients with high CC49 expression may benefit from more aggressive adjuvant chemotherapy regimens to reduce the risk of disease recurrence, whereas those with low CC49 expression may have a lower risk of recurrence and may require less intensive treatment.

Future Directions and Challenges

While the role of CC49 in CRC surgery outcome holds promise, several challenges and opportunities lie ahead. Further research is needed to validate the prognostic significance of CC49 in large, multicenter cohorts and to elucidate its underlying mechanisms of action in tumor progression and metastasis. Moreover, the development of standardized assays for assessing CC49 expression and its integration into routine clinical practice will be essential for translating these findings into meaningful improvements in patient care.

Conclusion

In conclusion, CC49 represents a promising biomarker for predicting outcomes in CRC surgery, with implications for perioperative management, postoperative surveillance, and treatment selection. By understanding the biological significance of CC49 and its association with surgical complications, disease recurrence, and survival outcomes, we can potentially improve patient outcomes and quality of life in CRC patients undergoing surgery. Continued research in this area will be crucial for realizing the full potential of CC49 as a prognostic marker and therapeutic target in CRC surgery.

References

[1] Jiang S, Zhang Y, Alsaikhan F, Jalil AT, Gol MK, Tarighatnia A. A meta-analysis review of the effect of Zn-doped synthetic polymer materials on bone regeneration. Journal of Drug Delivery Science and Technology. 2022 Oct 1;76:103792. [Google Scholar], [Publisher], [Crossref]

[2] Gol MK, Payami S, Lotfi A. Study of the effect of ear acupressure on stress and serum cortisol level before rhinoplasty surgery: a randomized clinical trial. Crescent Journal of Medical & Biological Sciences. 2020 Apr 1;7(2). [Google Scholar], [Publisher]

[3] Khanbabayi Gol M, Arefi N, Jafari M, Farzin H, Aghamohammadi D. Prevalence of Port-Related Infections and Their Predisposing Factors in Women with Breast Cancer under Chemotherapy. Iranian Quarterly Journal of Breast Disease. 2018

Sep 10;11(2):7-15. [Google Scholar], [Publisher], [Crossref]
[4] Piroozkhah, Moein, et al. "Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature." *Frontiers in Oncology* 13 (2023). [Google Scholar], [Publisher], [Crossref]
[5] AZHOUGH, RAMIN, et al. "Surgical Outcome and Complications of Lateral Internal Sphincterotomy in Chronic Anal Fissure-A Cross-sectional Study." Journal of Clinical & Diagnostic Research 15.12 (2021). [Google Scholar], [Publisher], [Crossref]
[6] Jalali, Pooya, et al. "UBE2C: A pan-cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis." *Cancer Reports* 7.4 (2024): e2032. [Google Scholar], [Publisher], [Crossref]
[7] Azhough, Ramin, et al. "Pilonidal sinus surgery with mechanical drilling technique." *Indian Journal of Surgery* 82 (2020): 824-827. [Google Scholar], [Publisher], [Crossref]
[8] Azhough, Ramin, et al. "Intradermal methylene blue analgesic application in posthemorrhoidectomy pain management: a randomized controlled trial." *Frontiers in Surgery* 11 (2024): 1354328. [Google Scholar], [Publisher], [Crossref]
[9] K Hadavand Mirzaei, et al., Application of Robotic Instruments in Hip Arthroplasty Surgery Based on Practical Tips a Systematic Review, Eurasian Journal of Chemical, Medicinal and Petroleum Research, **2024**, 3 (2), 593-609 [Google Scholar], [Publisher], [Crossref]
[10] S Sourili, What are the radiological criteria for identifying the Corona virus in CT scan images?, Eurasian Journal of Chemical, Medicinal and Petroleum Research (EJCMPR), **2024**, 3(2), 577-593 [Google Scholar], [Publisher], [Crossref]
[11] S Soubkari, Covid CT Chest Finding, Eurasian Journal of Chemical, Medicinal and Petroleum Research (EJCMPR), **2024**, 3(2), 563-576 [Google Scholar], [Publisher], [Crossref]
[12] S Asadimehr, Examining Drilling Problems and Practical Solutions Regarding them, Eurasian Journal of Chemical, Medicinal and Petroleum Research, **2024**, 3 (2), 552-562 [Google Scholar], [Publisher], [Crossref]
[13] S Asadimehr, Investigating the Use of Drilling Mud and the Reasons for its Use, Eurasian Journal of Chemical, Medicinal and Petroleum Research, **2024**, 3 (2), 543-551 [Google Scholar], [Publisher], [Crossref]
[14] S Soubhak, Nursing actions in patients undergoing laryngectomy in relation to reducing anxiety and depression, Eurasian Journal of Chemical, Medicinal and Petroleum Research, **2024**, 3 (2), 530-542 [Google Scholar], [Publisher], [Crossref]